Adolor starts 2nd Ph III trial of ADL 8-2698
Adolor Corp has started enrollment in a Phase III clinical trial of ADL8-2698, an investigational drug designed to help relieve bowel dysfunction in patients taking opioid narcotics for chronic pain. The compound recently started Phase III testing in patients with post-operative ileus.
ADL 8-2698 is an orally-active, small-molecule opioid receptor antagonist that works locally in the gastrointestinal tract. It does not cross the blood brain barrier or block the analgesic effects of opioid narcotics and, as such, is the first entry in a new class of peripherally-acting opioid blockers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze